<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079144</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000354491</org_study_id>
    <secondary_id>NCI-04-C-0104</secondary_id>
    <secondary_id>NCI-6233</secondary_id>
    <nct_id>NCT00079144</nct_id>
    <nct_alias>NCT00076661</nct_alias>
  </id_info>
  <brief_title>Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>Treatment Of Patients With Metastatic Melanoma Using Nonmyeloablative But Lymphocyte Depleting Regimen Followed By The Administration Of In Vitro Sensitized Lymphocytes Reactive With ESO-1 Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and fludarabine, work in&#xD;
      different ways to stop tumor cells from dividing so they stop growing or die. Treating a&#xD;
      person's lymphocytes in the laboratory and reinfusing them may replace immune cells destroyed&#xD;
      by chemotherapy. Vaccines made from peptides may make the body build an immune response to&#xD;
      kill tumor cells. Giving a vaccine with Montanide ISA-51 may cause a stronger immune response&#xD;
      and kill more tumor cells. Interleukin-2 may stimulate a person's lymphocytes to kill tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well lymphocyte-depleting nonmyeloablative (not&#xD;
      damaging to bone marrow) chemotherapy followed by autologous lymphocyte infusion, peptide&#xD;
      vaccine plus Montanide ISA-51, and interleukin-2 works in treating patients with metastatic&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the clinical tumor regression in patients with metastatic melanoma treated&#xD;
           with a lymphocyte-depleting nonmyeloablative preparative chemotherapy regimen followed&#xD;
           by autologous lymphocyte infusion, ESO-1 peptide vaccination comprising ESO-1:157-165&#xD;
           (165V) and Montanide ISA-51, and interleukin-2.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the survival of the infused lymphocytes in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the long-term immune status of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to type of lymphocyte infusion (ESO-1-reactive&#xD;
      tumor-infiltrating lymphocytes [TIL] vs ESO-1 reactive peripheral blood lymphocytes [PBL]).&#xD;
&#xD;
        -  Autologous lymphocyte collection and expansion: Autologous PBL or TIL are collected from&#xD;
           patients during leukapheresis or biopsy. The cells are sensitized in vitro with&#xD;
           ESO-1:157-165 (165V) melanoma antigen and expanded.&#xD;
&#xD;
        -  Lymphocyte-depleting nonmyeloablative preparative chemotherapy: Patients receive&#xD;
           lymphocyte-depleting nonmyeloablative preparative chemotherapy comprising&#xD;
           cyclophosphamide IV over 1 hour on days -7 and -6 and fludarabine IV over 15-30 minutes&#xD;
           on days -5 to -1.&#xD;
&#xD;
        -  Autologous lymphocyte infusion: Autologous PBL or TIL are reinfused on day 0*. Patients&#xD;
           also receive filgrastim (G-CSF) subcutaneously (SC) once daily beginning on day 1 and&#xD;
           continuing until blood counts recover.&#xD;
&#xD;
        -  ESO-1 peptide vaccination: Patients receive ESO-1 peptide vaccination comprising&#xD;
           ESO-1:157-165 (165V) peptide emulsified in Montanide ISA-51 SC on days 0*-4, 11, 18, and&#xD;
           25.&#xD;
&#xD;
        -  Interleukin therapy: Patients receive interleukin-2 IV over 15 minutes 3 times daily on&#xD;
           days 0*-4.&#xD;
&#xD;
      NOTE: *Day 0 is 1-4 days after the last dose of fludarabine.&#xD;
&#xD;
      Patients achieving stable disease or partial response may receive up to 1 retreatment course.&#xD;
      Patients with progressive disease after infusion of PBL may receive retreatment with TIL, if&#xD;
      available.&#xD;
&#xD;
      Patients are followed at 4-5 weeks, every 3-4 months for 2 years, and then annually&#xD;
      thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 24-74 patients (12-37 per stratum) will be accrued for this&#xD;
      study within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical tumor regression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival of infused lymphocytes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term immune status</measure>
  </secondary_outcome>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NY-ESO-1 peptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of metastatic melanoma that is refractory to standard therapy (including&#xD;
             high-dose interleukin-2)&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  HLA-A*0201 positive&#xD;
&#xD;
          -  Epstein-Barr virus positive&#xD;
&#xD;
          -  ESO-1-expressing disease by reverse transcription polymerase chain reaction amplified&#xD;
             tissue OR presence of ESO-1 serum antibody&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 8.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
          -  AST and ALT &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL (&lt; 3.0 mg/dL for patients with Gilbert's syndrome)&#xD;
&#xD;
          -  No coagulation disorders&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No major cardiovascular illness by stress thallium or comparable test&#xD;
&#xD;
          -  No cardiac arrhythmias&#xD;
&#xD;
          -  LVEF ≥ 45%&#xD;
&#xD;
          -  Normal cardiac stress test required for the following conditions:&#xD;
&#xD;
               -  Prior EKG abnormalities&#xD;
&#xD;
               -  Symptoms of cardiac ischemia&#xD;
&#xD;
               -  Arrhythmias&#xD;
&#xD;
               -  Age 50 and over&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  FEV_1 &gt; 60% of predicted (for patients with a prolonged history of cigarette smoking&#xD;
             or symptoms of respiratory dysfunction)&#xD;
&#xD;
          -  No obstructive or restrictive pulmonary disease&#xD;
&#xD;
          -  No other major respiratory illness&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No opportunistic infection&#xD;
&#xD;
          -  No major immune system illness&#xD;
&#xD;
          -  No form of primary or secondary immunodeficiency&#xD;
&#xD;
          -  No known hypersensitivity to study agents&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 4 months&#xD;
             after study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Prior ESO-1-based vaccination allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior nitrosoureas and recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent systemic steroid therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior systemic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Center for Cancer Research</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2005</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

